Compare Stocks: ANTX, GLAS, COLL, and ZVRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANTX Anthem	$5.05 +3.1%	$5.47	$1.00 ▼ $7.19	$190.57M	-0.99	194,131 shs	670,953 shs
COLL Collegium Pharmaceutical	$22.77 +1.7%	$29.16	$21.65 ▼ $50.79	$741.30M	0.72	836,598 shs	1.99 million shs
GLAS Glass House Brands	$7.89 -1.3%	$9.55	$5.15 ▼ $13.93	$747.59M	N/A	601,108 shs	676,183 shs
ZVRA Zevra Therapeutics	$11.61 -1.9%	$11.64	$7.51 ▼ $15.03	$689.45M	0.95	823,830 shs	1.48 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANTX Anthem	0.00%	-6.65%	-12.78%	+1.00%	+289.96%
COLL Collegium Pharmaceutical	0.00%	+0.09%	-17.32%	-32.11%	-35.93%
GLAS Glass House Brands	0.00%	-0.08%	-17.26%	+788,499,900.00%	+788,499,900.00%
ZVRA Zevra Therapeutics	0.00%	-3.33%	-2.35%	-10.00%	+58.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANTX Anthem	$5.05 +3.1%	$5.47	$1.00 ▼ $7.19	$190.57M	-0.99	194,131 shs	670,953 shs
COLL Collegium Pharmaceutical	$22.77 +1.7%	$29.16	$21.65 ▼ $50.79	$741.30M	0.72	836,598 shs	1.99 million shs
GLAS Glass House Brands	$7.89 -1.3%	$9.55	$5.15 ▼ $13.93	$747.59M	N/A	601,108 shs	676,183 shs
ZVRA Zevra Therapeutics	$11.61 -1.9%	$11.64	$7.51 ▼ $15.03	$689.45M	0.95	823,830 shs	1.48 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANTX Anthem	0.00%	-6.65%	-12.78%	+1.00%	+289.96%
COLL Collegium Pharmaceutical	0.00%	+0.09%	-17.32%	-32.11%	-35.93%
GLAS Glass House Brands	0.00%	-0.08%	-17.26%	+788,499,900.00%	+788,499,900.00%
ZVRA Zevra Therapeutics	0.00%	-3.33%	-2.35%	-10.00%	+58.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANTX Anthem	2.33	Hold	$9.00	78.22% Upside
COLL Collegium Pharmaceutical	2.50	Moderate Buy	$48.50	113.00% Upside
GLAS Glass House Brands	2.00	Hold	$16.00	102.92% Upside
ZVRA Zevra Therapeutics	2.90	Moderate Buy	$27.14	133.79% Upside

Current Analyst Ratings Breakdown

Latest ANTX, GLAS, COLL, and ZVRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	GLAS Glass House Brands	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)
9/9/2026	COLL Collegium Pharmaceutical	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
9/9/2026	COLL Collegium Pharmaceutical	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$58.00 ➝ $49.00
9/9/2026	COLL Collegium Pharmaceutical	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$58.00 ➝ $49.00
9/9/2026	COLL Collegium Pharmaceutical	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$45.00
9/4/2026	COLL Collegium Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D+)
8/20/2026	ZVRA Zevra Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	GLAS Glass House Brands	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/20/2026	ZVRA Zevra Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$26.00
8/19/2026	ZVRA Zevra Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/19/2026	COLL Collegium Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$56.00 ➝ $48.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANTX Anthem	N/A	N/A	N/A	N/A	$1.94 per share	N/A
COLL Collegium Pharmaceutical	$780.57M	0.95	$15.18 per share	1.50	$9.54 per share	2.39
GLAS Glass House Brands	N/A	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	$106.47M	6.48	$0.95 per share	12.27	$2.75 per share	4.22

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANTX Anthem	-$35.17M	-$1.07	N/A	N/A	N/A	N/A	-53.52%	-48.63%	N/A
COLL Collegium Pharmaceutical	$62.87M	$1.24	18.36	5.11	N/A	5.93%	91.43%	15.57%	11/5/2026 (Estimated)
GLAS Glass House Brands	N/A	N/A	N/A	39.43	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	$83.23M	$0.92	12.62	13.82	N/A	42.82%	54.54%	34.15%	11/4/2026 (Estimated)

Latest ANTX, GLAS, COLL, and ZVRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	ANTX Anthem	N/A	-$0.18	N/A	-$0.18	N/A	N/A
8/6/2026	Q2 2026	COLL Collegium Pharmaceutical	$1.72	$1.92	+$0.20	-$0.46	$199.63 million	$199.88 million
8/5/2026	Q2 2026	ZVRA Zevra Therapeutics	$0.11	$0.25	+$0.14	$0.14	$33.88 million	$39.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANTX Anthem	N/A	N/A	N/A	N/A	N/A
COLL Collegium Pharmaceutical	N/A	N/A	N/A	N/A	N/A
GLAS Glass House Brands	N/A	N/A	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANTX Anthem	N/A	14.32	14.32
COLL Collegium Pharmaceutical	3.32	1.03	0.84
GLAS Glass House Brands	N/A	N/A	N/A
ZVRA Zevra Therapeutics	N/A	5.17	5.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANTX Anthem	90.47%
COLL Collegium Pharmaceutical	N/A
GLAS Glass House Brands	N/A
ZVRA Zevra Therapeutics	35.03%

Insider Ownership

Company	Insider Ownership
ANTX Anthem	22.61%
COLL Collegium Pharmaceutical	1.85%
GLAS Glass House Brands	N/A
ZVRA Zevra Therapeutics	3.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANTX Anthem	N/A	37.74 million	29.20 million	Not Optionable
COLL Collegium Pharmaceutical	423	32.56 million	31.95 million	Optionable
GLAS Glass House Brands	357	93.80 million	N/A	N/A
ZVRA Zevra Therapeutics	61	59.38 million	57.19 million	Optionable

ANTX, GLAS, COLL, and ZVRA Headlines

Recent News About These Companies

Zevra Therapeutics, Inc. (ZVRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 15, 2026 | seekingalpha.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Recommendation of "Moderate Buy" from Analysts

September 13, 2026 | americanbankingnews.com

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Analysts

September 13, 2026 | marketbeat.com

Bank of America Corp DE Decreases Stock Position in Zevra Therapeutics, Inc. $ZVRA

September 8, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $2.85 Million in Zevra Therapeutics, Inc. $ZVRA

September 7, 2026 | marketbeat.com

Zevra Therapeutics to Present at Upcoming Investor Conferences

September 2, 2026 | globenewswire.com

Zevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual Symposium

August 25, 2026 | quiverquant.comQ

Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

August 25, 2026 | globenewswire.com

Globeflex Capital L P Invests $2.75 Million in Zevra Therapeutics, Inc. $ZVRA

August 24, 2026 | marketbeat.com

Roth MKM Sticks to Their Buy Rating for Zevra Therapeutics (ZVRA)

August 23, 2026 | theglobeandmail.com

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 21, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 13, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 11, 2026 | globenewswire.com

What Could Zevra Therapeutics (ZVRA) New NPC Data Mean For Its Europe Review?

August 7, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 6, 2026 | prnewswire.com

Zevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041

August 6, 2026 | seekingalpha.com

Zevra Therapeutics, Inc. (ZVRA) Q2 2026 Earnings Call Transcript

August 5, 2026 | seekingalpha.com

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

August 5, 2026 | zacks.com

Zevra Therapeutics (ZVRA) Releases Q2 2026 Earnings: Revenue Growth and EPS Beat

August 5, 2026 | quiverquant.comQ

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

August 5, 2026 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA

August 4, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANTX, GLAS, COLL, and ZVRA Company Descriptions

Anthem NASDAQ:ANTX

$5.05 +0.15 (+3.06%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.04 -0.01 (-0.20%)

As of 09/18/2026 07:30 PM Eastern

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial & Specialty Business, Government Business, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small group, individual, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, such as consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care guidance; and Medicare administrative services. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2017, it served 40.2 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.

Collegium Pharmaceutical NASDAQ:COLL

$22.77 +0.39 (+1.74%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$22.80 +0.03 (+0.13%)

As of 09/18/2026 07:30 PM Eastern

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Glass House Brands NYSE:GLAS

$7.88 -0.11 (-1.31%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$8.02 +0.13 (+1.65%)

As of 09/18/2026 07:41 PM Eastern

Glass House Brands is a vertically integrated cannabis company. Glass House Brands is based in LONG BEACH, Calif.

Zevra Therapeutics NASDAQ:ZVRA

$11.61 -0.23 (-1.94%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$11.64 +0.04 (+0.30%)

As of 09/18/2026 07:59 PM Eastern

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANTX, GLAS, COLL, and ZVRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANTX, GLAS, COLL, and ZVRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANTX, GLAS, COLL, and ZVRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANTX, GLAS, COLL, and ZVRA Company Descriptions

Anthem NASDAQ:ANTX

Collegium Pharmaceutical NASDAQ:COLL

Glass House Brands NYSE:GLAS

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANTX, GLAS, COLL, and ZVRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANTX, GLAS, COLL, and ZVRA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANTX, GLAS, COLL, and ZVRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANTX, GLAS, COLL, and ZVRA Company Descriptions

Anthem NASDAQ:ANTX

Collegium Pharmaceutical NASDAQ:COLL

Glass House Brands NYSE:GLAS

Zevra Therapeutics NASDAQ:ZVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools